Newborn screening of duchenne muscular dystrophy specifically targeting deletions amenable to exon-skipping therapy.

Abstract excerpt

Duchenne Muscular Dystrophy (DMD) is a lethal progressive muscle-wasting disease. New treatment strategies relying on DMD gene exon-skipping therapy have recently been approved and about 30% of patients could be amenable to exon 51, 53 or 45 skipping. We evaluated the spectrum of deletions reported in DMD registries, and designed a method to screen newborns and identify DMD deletions amenable to exon 51, 53 and...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Dystrophin
• Share to Dried Blood Spot Testing